Education
About Us
Working with TipRanks
Follow Us
Scandion Oncology A/S (SE:SCOL)
:SCOL
RESEARCH TOOLSreports
Top Page
Scandion Oncology A/S
(Frankfurt:SCOL)
Rating:30Underperform
Price Target:―
Scandion Oncology A/S (SCOL) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
€4.46M
Dividend YieldN/A
Average Volume (3M)3.91M
Price to Earnings (P/E)―
Beta (1Y)0.25
Revenue GrowthN/A
EPS Growth57.91%
CountrySE
Employees4
SectorHealthcare
Sector Strength41
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.10
Shares Outstanding234,761,410
10 Day Avg. Volume1,480,745
30 Day Avg. Volume3,906,183
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.06
Price to Sales (P/S)0.00
P/FCF Ratio-0.08
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Scandion Oncology A/S Business Overview & Revenue Model
Company DescriptionScandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of chemotherapy resistance. Its lead product candidate includes the SCO-101, an oral compound that is in clinical Phase Ib and Phase II studies in cancer patients. The company's other product candidate is SCO-201, which is in preclinical trial for the treatment of solid tumors. Scandion Oncology A/S was founded in 2017 and is headquartered in Copenhagen, Denmark.
How the Company Makes MoneyScandion Oncology A/S makes money through the development and commercialization of its drug candidates aimed at reversing cancer drug resistance. The company's revenue model primarily involves research and development collaborations, licensing agreements, and potential milestone payments from pharmaceutical partners. These partnerships can include upfront payments, research funding, and royalties on the sales of successfully marketed drugs. Additionally, Scandion Oncology may receive governmental or institutional grants to support their innovative research efforts. As the company's drug candidates progress through clinical trials and achieve regulatory approvals, these financial streams become crucial in driving growth and sustaining operations.
Scandion Oncology A/S Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | |||||
| TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 205.44K | Gross Profit |
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -11.16M | EBIT |
| -38.31M | -45.36M | -80.17M | -55.37M | -22.89M | -15.39M | EBITDA |
| -37.46M | -45.53M | -80.82M | -56.10M | -22.85M | -15.60M | Net Income Common Stockholders |
| -32.47M | -39.20M | -76.70M | -51.70M | -16.27M | -12.18M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 26.52M | 26.52M | 77.61M | 105.71M | 5.81M | 15.42M | Total Assets |
| 34.56M | 34.56M | 89.40M | 116.22M | 186.41M | 19.90M | Total Debt |
| 499.00K | 499.00K | 1.60M | 1.22M | 316.00K | 1.42K | Net Debt |
| -26.02M | -26.02M | -76.01M | -104.49M | -5.50M | -15.42M | Total Liabilities |
| 3.44M | 3.44M | 19.07M | 11.68M | 30.54M | 1.56M | Stockholders Equity |
| 31.12M | 31.12M | 70.33M | 104.54M | 155.87M | 18.34M |
| Cash Flow | Free Cash Flow | ||||
| -35.72M | -50.67M | -69.86M | -50.12M | -17.50M | -10.20M | Operating Cash Flow |
| -35.72M | -50.67M | -69.44M | -49.80M | -17.45M | -9.96M | Investing Cash Flow |
| 510.00K | 288.00K | -389.00K | -485.00K | -46.00K | -238.28K | Financing Cash Flow |
| 13.69M | -705.00K | 41.73M | 150.18M | 7.89M | 17.95M |
Scandion Oncology A/S Technical Analysis
Negative
0.02
Price Trends
0.01
Positive
0.03
Negative
0.07
Negative
Market Momentum
<0.01
Positive
49.77
Neutral
61.11
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:SCOL, the sentiment is Negative. The current price of 0.02 is above the 20-day moving average (MA) of 0.02, above the 50-day MA of 0.01, and below the 200-day MA of 0.07, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 49.77 is Neutral, neither overbought nor oversold. The STOCH value of 61.11 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:SCOL.
Scandion Oncology A/S Peers Comparison
Overall Rating
UnderperformOutperform
Sector (54)
Financial Indicators
Performance Comparison
SE:SCOL
Scandion Oncology A/S
0.02
-0.37
-95.64%
DE:5LD
LIDDS AB
0.01
0.00
0.00%
DE:1XT
Xintela AB
0.03
0.02
200.00%
DE:9RP
Lipigon Pharmaceuticals AB
0.02
0.01
100.00%
DE:COJ0
CombiGene AB
0.17
-0.07
-29.17%
DE:5JA1
Sprint Bioscience AB
0.02
-0.08
-80.00%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.